Protein detail
CD86
T-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4 counter-receptor B7.2) (FUN-1) (CD antigen CD86)
Entry name CD86 | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 5 | Transmembrane count 1 | Protein classification CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information13
Protein Names
T-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4 counter-receptor B7.2) (FUN-1) (CD antigen CD86)
Protein Class (4)
CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins
Protein Function (3)
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Transmembrane
248..268; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym (3)
B7-2B7.2CD28LG2
Gene Description
CD86 molecule
Chromosome
3
Position
122055362-122121139
Supporting publications (n)
5
EVMP confidence score
0.50
Fluorescence & Localization6
Tissue SpecificlungCell SpecificB-cellsSingle-Nuclei Brain Specificcentral nervous system macrophageBlood Cell Specificmyeloid DCBlood Lineage SpecificB-cells
Function & Pathway7
Protein Function (3)
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Cellular Component (5)
Molecular Function (5)
Biological Process (3)
KEGG (14)
- hsa03267 Virion - Adenovirus
- KEGG:hsa04514 Cell adhesion molecule (CAM) interaction
- KEGG:hsa04517 IgSF CAM signaling
- KEGG:hsa04620 Toll-like receptor signaling pathway
- KEGG:hsa04672 Intestinal immune network for IgA production
- KEGG:hsa04940 Type I diabetes mellitus
- KEGG:hsa05167 Kaposi sarcoma-associated herpesvirus infection
- KEGG:hsa05202 Transcriptional misregulation in cancer
- KEGG:hsa05320 Autoimmune thyroid disease
- KEGG:hsa05322 Systemic lupus erythematosus
Page 1 of 2
Reactome (14)
- R-hsa-1280218 adaptive immune system
- R-hsa-389357 cd28 dependent pi3k akt signaling
- R-hsa-389359 cd28 dependent vav1 pathway
- R-hsa-2219530 constitutive signaling by aberrant pi3k in cancer
- R-hsa-389513 co inhibition by ctla4
- R-hsa-389356 co stimulation by cd28
- R-hsa-1280215 cytokine signaling in immune system
- R-hsa-5663202 diseases of signal transduction by growth factor receptors and second messengers
- R-hsa-6783783 interleukin 10 signaling
- R-hsa-9006925 intracellular signaling by second messengers
Page 1 of 2
Mediation Categories (5)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence49
Ligand-Receptor Signaling (45)
45 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | CellPhoneDB | No | Yes | Yes | Yes | No |
| receptor | receptor | GO_Intercell | No | Yes | Yes | Yes | No |
| receptor | receptor | Baccin2019 | No | Yes | Yes | Yes | No |
| receptor | receptor | OmniPath | No | Yes | Yes | Yes | No |
| extracellular | extracellular | DGIdb | No | No | Yes | Yes | No |
| extracellular | extracellular | LOCATE | No | No | Yes | Yes | No |
| extracellular | extracellular | OmniPath | No | No | Yes | Yes | No |
| intracellular | intracellular | LOCATE | No | No | Yes | Yes | No |
| intracellular | intracellular | ComPPI | No | No | Yes | Yes | No |
| intracellular | intracellular | GO_Intercell | No | No | Yes | Yes | No |
Page 1 of 5Next
Regulatory Interaction Network (1)
1 record.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| MARH1 | Q8TCQ1 | CD86 | P42081 | Yes | No | Yes | SIGNOR | SIGNOR:21849678 |
Protein Complex Composition (2)
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Mass spectrometry | 0 |
Sequence, Structure & Domains12
Sequences
Length
329
Mass
37,682
Sequence
MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF
Alternative Products
Event=Alternative splicing; Named isoforms=6; Name=1; IsoId=P42081-1; Sequence=Displayed; Name=2; IsoId=P42081-3; Sequence=VSP_023124; Name=3; Synonyms=CD86 deltaEC; IsoId=P42081-2; Sequence=VSP_023124, VSP_009125; Name=4; Synonyms=CD86 deltaTM; IsoId=P42081-4; Sequence=VSP_023124, VSP_040324; Name=5; IsoId=P42081-5; Sequence=VSP_047221; Name=6; IsoId=P42081-6; Sequence=VSP_047220
Alternative Sequence
1..82; Missing (in isoform 6); 1..6; Missing (in isoform 2, isoform 3 and isoform 4); 22..234; Missing (in isoform 3); 22..133; Missing (in isoform 5); 235..282; Missing (in isoform 4)
3D Structural Models
Turn
90..93
Helix
50..52; 80..82; 102..104
Beta Strand
26..31; 36..39; 53..59; 64..69; 72..74; 76..78; 85..89; 94..97; 106..115; 117..133
3D Structure
Electron microscopy (4); X-ray crystallography (3)
Domain & Motif Annotations
Compositional Bias
287..312; Basic and acidic residues
Domain (FT)
33..131; Ig-like V-type; 150..225; Ig-like C2-type
Region
277..329; Disordered
Clinical Relevance7
Disease Involvement
FDA approved drug targets
Drug Targets
FDA approved drug targets
Drugs (10)
Interaction Protein
ENSG00000163599
Interaction Count
1
Interaction Dataset
intact_biogrid
Supporting Publications5
| PMID | Title | Abstract |
|---|---|---|
| 12645951 | Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. | Exosomes express the glycosylphosphatidylinositol (GPI)-anchored regulators CD55 and CD59, but not the transmembrane protein CD46. We conclude that exosomes express GPI-anchored complement regulators in order to permit their survival in the extracellular environment. We have examined the expression and functional roles of the membrane regulators of complement (CD46, CD55 and CD59) on antigen-presenting cell-derived exosomes. |
| 36359760 | Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. | No abstract available |
| 36587540 | Isolation of extracellular vesicles from bitch's amnion-derived cells culture and their CD59 expression: Preliminary results. | No abstract available |
| 36612172 | Extracellular Vesicle Membrane Protein Profiling and Targeted Mass Spectrometry Unveil CD59 and Tetraspanin 9 as Novel Plasma Biomarkers for Detection of Colorectal Cancer. | No abstract available |
| 37115163 | A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis. | As psoriatic stratum corneums are uniquely characterized by activated complements and Munro microabscesses, we postulated that topically applied exosomes permeate the psoriatic stratum corneum to inhibit C5b9 complement complex through CD59, and this inhibition attenuated neutrophil secretion of IL-17. |